Medicine guide

Sunosi

·

  • Prescription status not stated
  • Pain, sleep, mood, epilepsy and the brain
Active substance
Solriamfetol
Made by
Atnahs Pharma Netherlands B.V.

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

  • Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy). Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP).

From the official label · 2026-09-30 · European Medicines Agency

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

United StatesNo exact match for this strength and form

SpainNo exact match for this strength and form

CanadaNo exact match for this strength and form

NetherlandsNo exact match for this strength and form

SwitzerlandNo exact match for this strength and form

Details

Made byAtnahs Pharma Netherlands B.V.
Active substanceSolriamfetol
Used inPain, sleep, mood, epilepsy and the brain
ClassificationN06BA14 · Pain, sleep, mood, epilepsy and the brain
Additional monitoring ▼Yes — under additional monitoring (black triangle). Report suspected side effects.
Authorised on2020-01-16
Last updated by the regulator2026-05-27
EMA product numberEMEA/H/C/004893

Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician

Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).